GTP 14564 is an inhibitor of class III receptor tyrosine kinases (IC50s = 0.3 μM for c-Fms, c-Kit, ITD-FLT3 and 1 μM for PDGFRβ). It is without effect against a panel of non-receptor tyrosine and serine/threonine kinases. GTP 14564 blocks the proliferation of leukemia cells stimulated with FLT3 ligand by preventing the activation of STAT5.
Potent, selective inhibitor of class III receptor tyrosine kinases (IC 50 values are 0.3 μ M for c-Fms, c-Kit, FLT3 and ITD-FLT3 and 1 μ M for PDGFR β ). Displays no selectivity for ERK1, ERK2, EGFR, MEK1, HER2, Src, Abl, PKC, PKA and Akt (IC50 > 10 μ M). Inhibits FL-dependent proliferation in BaF/ITD-FLT3 cells more potently than BaF/wt-FLT3 cells; anti-leukaemic.
[1] KEN MURATA. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).[J]. The Journal of Biological Chemistry, 2003, 278 35: 32892-32898. DOI:
10.1074/jbc.m210405200[2] Q YAO. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway[J]. Leukemia, 2005, 19 9: 1605-1612. DOI:
10.1038/sj.leu.2403881